Acrivon COO awarded 186,728 stock options

Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe received a grant of stock options covering 186,728 shares of common stock.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe received a grant of stock options covering 186,728 shares of common stock. The Form 4 classifies this as a grant or award acquisition, not an open-market purchase or sale.

According to the vesting terms, 25% of the option vests on March 1, 2027, and the remaining shares vest in 36 substantially equal monthly installments thereafter, provided Devroe remains in continuous service through each vesting date.

Insider Trade Summary

Grant/Award: 186,728 shares

Grant/Award 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	186,728	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 186,728 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Acrivon Therapeutics (ACRV) Form 4 for Eric Devroe report?

The Form 4 reports that Acrivon Therapeutics (ACRV) Chief Operating Officer Eric Devroe received a grant of stock options. The options cover 186,728 shares of common stock and are classified as a grant or award acquisition rather than a market purchase or sale.

How many stock options did Acrivon (ACRV) grant to COO Eric Devroe?

Acrivon Therapeutics (ACRV) granted Chief Operating Officer Eric Devroe stock options for 186,728 shares. This entire amount is reported as directly owned following the transaction, reflecting a single grant rather than multiple trades or a series of separate acquisitions or dispositions.

What is the vesting schedule for Eric Devroe’s ACRV stock options?

The vesting schedule for Eric Devroe’s ACRV stock options provides that 25% of the shares vest on March 1, 2027. The remaining shares vest in 36 substantially equal monthly installments afterward, conditioned on his continuous service through each vesting date.

Is Eric Devroe buying or selling ACRV shares in this Form 4 filing?

Eric Devroe is not buying or selling ACRV shares on the open market in this filing. The Form 4 records a grant or award acquisition of stock options, meaning he received options as compensation rather than executing a market purchase or sale transaction.

What role does Eric Devroe hold at Acrivon Therapeutics (ACRV)?

Eric Devroe serves as Chief Operating Officer at Acrivon Therapeutics (ACRV). His position is disclosed in the insider filing, which reports the grant of stock options and identifies him as an officer rather than a director or ten percent beneficial owner of the company.

Are there conditions attached to vesting of Eric Devroe’s ACRV options?

Yes. Vesting of Eric Devroe’s ACRV stock options is subject to his continuous service. Twenty-five percent vests on March 1, 2027, and the remaining shares vest in 36 equal monthly installments only if he remains in service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:16 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		186,728		(1)	02/29/2036	Common Stock	186,728	$0	186,728	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.